Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the incidence of heart failure and renal events in type 2 diabetes patients at risk for cardiovascular disease, as well as in patients with diabetes and chronic kidney disease [1,2,3,4]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.